MORPHOSYS AG O.N.

Premiumpartner

Firmenbeschreibung

Die MorphoSys AG ist ein globales, kommerziell ausgerichtetes Biopharma-Unternehmen. MorphoSys vermarktet sein eigenes Medikament Monjuvi in den USA – eine Krebsimmuntherapie in Kombination mit Lenalidomid für die Zweit- und Drittlinien-Behandlung von Patienten mit diffusem großzelligen B-Zell-Lymphom (DLBCL), die nicht für eine Stammzellentherapie in Frage kommen. Tafasitamab wird zudem in einer globalen Studie als mögliche Erstlinientherapie bei DLBCL untersucht. Zwei weitere Produktkandidaten für onkologische Indikationen befinden sich in der späten und mittleren klinischen Entwicklungsphase: Pelabresib, ein selektiver niedermolekularer BET-Inhibitor, wird als potenzielle Behandlungsmöglichkeit für Myelofibrose entwickelt – eine Form von Knochenmarkkrebs mit begrenzten Behandlungsmöglichkeiten; und CPI-0209, ein EZH2-Hemmer der zweiten Generation, der zur Behandlung hämatologischer und solider Tumore untersucht wird. MorphoSys hat seinen Hauptsitz in Planegg bei München und führt sein Geschäft in den USA von Boston, Massachusetts.

KeyData

endOfFinancialYear: 31.12.2022 00:00
stockholderStructure: Kynam Capital Management, LP (9.8%),UBS Group (8.05%),Morgan Stanley (7.18%),JPMorgan Chase & Co. (6.61%),DWS Investment GmbH (4.12%)
sharesOutstanding: 37618139.0000
ceo: Dr. Jean-Paul Kress
board: Lucinda Crabtree, Ph.D., Tim Demuth, M.D., Ph.D., Barbara Krebs-Pohl, Ph.D., Joe Horvat, Luisa Ciccarelli, Thomas Biegi, Charlotte Lohmann
supervisoryBoard: Dr. Marc Cluzel, Dr. George Golumbeski, Krisja Vermeylen, Michael Brosnan, Sharon Curran, Andrew Cheng, M.D., Ph.D.
countryID: 2
freeFloat: 70.6000
faceValueCurrencyID: 1
faceValueCurrency: EUR
sectorName: Biotechnologie
industryName: Biotechnologie
subsectorName: Biotechnologie
country: Deutschland
countryName: Deutschland

Kontakt

name: Dr. Julia Neugebauer
phone: +49 89 89927 179
email: investors@morphosys.com
irWebSite: https://www.morphosys.com/de/investoren

Adresse

street: Semmelweisstr. 7
city: D-82152 Martinsried/Planegg
phone: +49-89-89927-0
fax: +49-89-89927-222
webSite: www.morphosys.de
email: info@morphosys.de

Finanzen (kurz)

year: 2021 cash: 123.2000
balanceSheetTotal: 2556.3000 liabilities: 2311.4000
totalShareholdersEquity: 244.9000 sales: 179.6000
investment: 96.6000 incomeBeforeTaxes: -591.1000
netIncome: -514.5000 cashFlow: 13.5000
employees: 732 currencyID: 1
units: 1000000 currency: EUR
year: 2022 cash: 402.4000
balanceSheetTotal: 2396.9000 liabilities: 2239.5000
totalShareholdersEquity: 157.4000 sales: 278.3000
investment: 412.0000 incomeBeforeTaxes: -319.6000
netIncome: -151.0000 employees: 629
currencyID: 1 units: 1000000
currency: EUR
year: 2023 cash: 158.5000
balanceSheetTotal: 2026.3000 liabilities: 1977.3000
totalShareholdersEquity: 49.0000 sales: 238.3000
investment: 213.4000 incomeBeforeTaxes: -188.5000
netIncome: -189.7000 employees: 524
currencyID: 1 units: 1000000
currency: EUR

Finanzen (kurz)

year: 2021
cash: 123.2000
balanceSheetTotal: 2556.3000
liabilities: 2311.4000
totalShareholdersEquity: 244.9000
sales: 179.6000
investment: 96.6000
incomeBeforeTaxes: -591.1000
netIncome: -514.5000
cashFlow: 13.5000
employees: 732
currencyID: 1
units: 1000000
currency: EUR
year: 2022
cash: 402.4000
balanceSheetTotal: 2396.9000
liabilities: 2239.5000
totalShareholdersEquity: 157.4000
sales: 278.3000
investment: 412.0000
incomeBeforeTaxes: -319.6000
netIncome: -151.0000
employees: 629
currencyID: 1
units: 1000000
currency: EUR
year: 2023
cash: 158.5000
balanceSheetTotal: 2026.3000
liabilities: 1977.3000
totalShareholdersEquity: 49.0000
sales: 238.3000
investment: 213.4000
incomeBeforeTaxes: -188.5000
netIncome: -189.7000
employees: 524
currencyID: 1
units: 1000000
currency: EUR

Finanzen (ausführlich)

year: 2022 units: 1000000
balanceSheetTotal: 2396.9000 cash: 402.4000
currentAssets: 1089.0000 fixedAssets: 1307.9000
liabilities: 278.3000 nonCurrentLiabilities: 1961.2000
totalLiabilitiesEquity: 2396.9000 provisions: 21.2000
totalShareholdersEquity: 157.4000 employees: 629
property: 5.9000 intangibleAssets: 886.6000
longTermInvestments: 0.0000 inventories: 24.3000
accountsReceivable: 91.2000 accountsPayable: 157.3000
liabilitiesTotal: 2239.5000 longTermDebt: 1945.9000
sales: 278.3000 netIncome: -151.0000
operatingResult: -220.7000 incomeInterest: 577.9000
investments: 297.8000 incomeTaxes: 168.6000
costGoodsSold: 48.6000 grossProfit: 229.7000
revenuePerEmployee: 442448.3307 cashFlow: -366.7000
cashFlowInvesting: 345.0000 cashFlowFinancing: 311.4000
accountingStandard: IFRS equityRatio: 6.5668
debtEquityRatio: 1422.8081 liquidityI: 144.5922
liquidityII: 177.3626 netMargin: -54.2580
grossMargin: 82.5368 cashFlowMargin: -131.7643
ebitMargin: -79.3029 ebitdaMargin: 0.0000
preTaxROE: -203.0496 preTaxROA: -13.3339
roe: -95.9339 roa: -6.2998
netIncomeGrowth: -70.6511 revenuesGrowth: 54.9555
taxExpenseRate: -52.7534 equityTurnover: 1.7681
epsBasic: -4.4200 epsBasicGrowth: -71.2987
incomeBeforeTaxes: -319.6000 priceCashFlowRatio: -1.2332
bookValuePerShare: 4.5980 marketCap: 452203967.0300
earningsYield: -33.4595 cashFlowPerShare: -10.7122
priceBookValueRatio: 2.8730 netEarningsPerShare: -4.4111
currency: EUR
year: 2023 units: 1000000
balanceSheetTotal: 2026.3000 cash: 158.5000
currentAssets: 814.0000 fixedAssets: 1212.3000
liabilities: 264.3000 nonCurrentLiabilities: 264.3000
totalLiabilitiesEquity: 2026.3000 provisions: 39.0000
totalShareholdersEquity: 49.0000 employees: 524
property: 3.9000 intangibleAssets: 844.1000
longTermInvestments: 2.4000 inventories: 62.1000
accountsReceivable: 32.1000 accountsPayable: 109.8000
liabilitiesTotal: 1977.3000 longTermDebt: 1669.2000
shortTermDebt: 126.9000 minorityInterests: 0.0000
sales: 238.3000 netIncome: -189.7000
operatingResult: -252.5000 incomeInterest: 71.4000
investments: 283.6000 incomeTaxes: 1.2000
costGoodsSold: 58.4000 grossProfit: 179.9000
minorityInterestsProfit: 0.0000 revenuePerEmployee: 454770.9924
cashFlow: -295.8000 cashFlowInvesting: 15.4000
cashFlowFinancing: 43.0000 accountingStandard: IFRS
equityRatio: 2.4182 debtEquityRatio: 4035.3061
liquidityI: 59.9697 liquidityII: 72.1150
netMargin: -79.6055 grossMargin: 75.4931
cashFlowMargin: -124.1292 ebitMargin: -105.9589
ebitdaMargin: 0.0000 preTaxROE: -384.6939
preTaxROA: -9.3027 roe: -387.1429
roa: -9.3619 netIncomeGrowth: 25.6291
revenuesGrowth: -14.3730 taxExpenseRate: -0.6366
equityTurnover: 4.8633 epsBasic: -5.5300
epsBasicGrowth: 25.1131 incomeBeforeTaxes: -188.5000
priceCashFlowRatio: -4.3220 bookValuePerShare: 1.3031
marketCap: 1278449368.0000 earningsYield: -16.2647
cashFlowPerShare: -7.8667 netAssetsPerShare: 1.3031
priceBookValueRatio: 26.0908 netEarningsPerShare: -5.0450
currency: EUR
year: 2024 priceCashFlowRatio: -8.3898
bookValuePerShare: 1.3031 marketCap: 2481695832.0000
earningsYield: -8.3788 pegRatio: -0.4752
cashFlowPerShare: -7.8667 netAssetsPerShare: 1.3031
priceBookValueRatio: 50.6469 netEarningsPerShare: -5.0450
currency: EUR

Finanzen (ausführlich)

year: 2022
units: 1000000
balanceSheetTotal: 2396.9000
cash: 402.4000
currentAssets: 1089.0000
fixedAssets: 1307.9000
liabilities: 278.3000
nonCurrentLiabilities: 1961.2000
totalLiabilitiesEquity: 2396.9000
provisions: 21.2000
totalShareholdersEquity: 157.4000
employees: 629
property: 5.9000
intangibleAssets: 886.6000
longTermInvestments: 0.0000
inventories: 24.3000
accountsReceivable: 91.2000
accountsPayable: 157.3000
liabilitiesTotal: 2239.5000
longTermDebt: 1945.9000
sales: 278.3000
netIncome: -151.0000
operatingResult: -220.7000
incomeInterest: 577.9000
investments: 297.8000
incomeTaxes: 168.6000
costGoodsSold: 48.6000
grossProfit: 229.7000
revenuePerEmployee: 442448.3307
cashFlow: -366.7000
cashFlowInvesting: 345.0000
cashFlowFinancing: 311.4000
accountingStandard: IFRS
equityRatio: 6.5668
debtEquityRatio: 1422.8081
liquidityI: 144.5922
liquidityII: 177.3626
netMargin: -54.2580
grossMargin: 82.5368
cashFlowMargin: -131.7643
ebitMargin: -79.3029
ebitdaMargin: 0.0000
preTaxROE: -203.0496
preTaxROA: -13.3339
roe: -95.9339
roa: -6.2998
netIncomeGrowth: -70.6511
revenuesGrowth: 54.9555
taxExpenseRate: -52.7534
equityTurnover: 1.7681
epsBasic: -4.4200
epsBasicGrowth: -71.2987
incomeBeforeTaxes: -319.6000
priceCashFlowRatio: -1.2332
bookValuePerShare: 4.5980
marketCap: 452203967.0300
earningsYield: -33.4595
cashFlowPerShare: -10.7122
priceBookValueRatio: 2.8730
netEarningsPerShare: -4.4111
currency: EUR
year: 2023
units: 1000000
balanceSheetTotal: 2026.3000
cash: 158.5000
currentAssets: 814.0000
fixedAssets: 1212.3000
liabilities: 264.3000
nonCurrentLiabilities: 264.3000
totalLiabilitiesEquity: 2026.3000
provisions: 39.0000
totalShareholdersEquity: 49.0000
employees: 524
property: 3.9000
intangibleAssets: 844.1000
longTermInvestments: 2.4000
inventories: 62.1000
accountsReceivable: 32.1000
accountsPayable: 109.8000
liabilitiesTotal: 1977.3000
longTermDebt: 1669.2000
shortTermDebt: 126.9000
minorityInterests: 0.0000
sales: 238.3000
netIncome: -189.7000
operatingResult: -252.5000
incomeInterest: 71.4000
investments: 283.6000
incomeTaxes: 1.2000
costGoodsSold: 58.4000
grossProfit: 179.9000
minorityInterestsProfit: 0.0000
revenuePerEmployee: 454770.9924
cashFlow: -295.8000
cashFlowInvesting: 15.4000
cashFlowFinancing: 43.0000
accountingStandard: IFRS
equityRatio: 2.4182
debtEquityRatio: 4035.3061
liquidityI: 59.9697
liquidityII: 72.1150
netMargin: -79.6055
grossMargin: 75.4931
cashFlowMargin: -124.1292
ebitMargin: -105.9589
ebitdaMargin: 0.0000
preTaxROE: -384.6939
preTaxROA: -9.3027
roe: -387.1429
roa: -9.3619
netIncomeGrowth: 25.6291
revenuesGrowth: -14.3730
taxExpenseRate: -0.6366
equityTurnover: 4.8633
epsBasic: -5.5300
epsBasicGrowth: 25.1131
incomeBeforeTaxes: -188.5000
priceCashFlowRatio: -4.3220
bookValuePerShare: 1.3031
marketCap: 1278449368.0000
earningsYield: -16.2647
cashFlowPerShare: -7.8667
netAssetsPerShare: 1.3031
priceBookValueRatio: 26.0908
netEarningsPerShare: -5.0450
currency: EUR
year: 2024
priceCashFlowRatio: -8.3898
bookValuePerShare: 1.3031
marketCap: 2481695832.0000
earningsYield: -8.3788
pegRatio: -0.4752
cashFlowPerShare: -7.8667
netAssetsPerShare: 1.3031
priceBookValueRatio: 50.6469
netEarningsPerShare: -5.0450
currency: EUR